DE69329559D1 - Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen - Google Patents

Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen

Info

Publication number
DE69329559D1
DE69329559D1 DE69329559T DE69329559T DE69329559D1 DE 69329559 D1 DE69329559 D1 DE 69329559D1 DE 69329559 T DE69329559 T DE 69329559T DE 69329559 T DE69329559 T DE 69329559T DE 69329559 D1 DE69329559 D1 DE 69329559D1
Authority
DE
Germany
Prior art keywords
pct
treatment
mannose
fibrotic disorders
phosphates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69329559T
Other languages
English (en)
Other versions
DE69329559T2 (de
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of DE69329559D1 publication Critical patent/DE69329559D1/de
Application granted granted Critical
Publication of DE69329559T2 publication Critical patent/DE69329559T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
DE69329559T 1992-03-17 1993-03-16 Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen Expired - Lifetime DE69329559T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929205800A GB9205800D0 (en) 1992-03-17 1992-03-17 Treatment of fibrotic disorders
PCT/GB1993/000541 WO1993018777A1 (en) 1992-03-17 1993-03-16 Use of mannose phosphates for the treatment of fibrotic disorders

Publications (2)

Publication Number Publication Date
DE69329559D1 true DE69329559D1 (de) 2000-11-16
DE69329559T2 DE69329559T2 (de) 2001-05-31

Family

ID=10712310

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329559T Expired - Lifetime DE69329559T2 (de) 1992-03-17 1993-03-16 Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen

Country Status (18)

Country Link
US (1) US5520926A (de)
EP (1) EP0728006B1 (de)
JP (1) JP3930556B2 (de)
AT (1) ATE196847T1 (de)
AU (1) AU667887B2 (de)
CA (1) CA2130805C (de)
DE (1) DE69329559T2 (de)
DK (1) DK0728006T3 (de)
ES (1) ES2151903T3 (de)
GB (2) GB9205800D0 (de)
GR (1) GR3035117T3 (de)
IL (1) IL105079A (de)
NO (1) NO306808B1 (de)
NZ (1) NZ249915A (de)
PT (1) PT728006E (de)
SG (1) SG49899A1 (de)
WO (1) WO1993018777A1 (de)
ZA (1) ZA931869B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
SE9403137D0 (sv) * 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
US6566339B1 (en) 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB9516012D0 (en) * 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
GB9616896D0 (en) * 1996-08-12 1996-09-25 British Tech Group Pharmaceutical compositions
US6093388A (en) * 1996-08-12 2000-07-25 Btg International Limited Mannose-6-phosphate composition and its use in treating fibrotic disorders
DE19758059C2 (de) * 1997-12-29 2001-10-04 Thorsten Marquardt Verwendung von Mannose zur Bekämpfung der Proteinverlust-Enteropathie
WO2002030432A1 (en) * 2000-06-23 2002-04-18 Cambridgemed, Inc Agent for reduction of scar formation by using wound alkalinization
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
US20030031689A1 (en) * 2001-08-09 2003-02-13 Thomas Mammone Method of skin exfoliation
US6822033B2 (en) 2001-11-19 2004-11-23 United States Gypsum Company Compositions and methods for treating set gypsum
EP1478354A4 (de) * 2002-01-22 2008-09-24 Genzyme Corp Verwendung von tgf-beta-antagonisten zur behandlung oder prävention von chronischer transplantatabstossung
KR100518152B1 (ko) * 2002-05-09 2005-09-29 메디제네스(주) 혈장 또는 혈청을 함유한 창상 치료용 약학 조성물
GB0217136D0 (en) 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
KR100492913B1 (ko) * 2002-08-23 2005-06-03 주식회사 태평양 피부 감작 및 자극을 완화하는 피부 외용제 조성물
US20050136126A1 (en) * 2003-03-17 2005-06-23 Cambridgemed, Inc. Agent for reduction of scar formation by using wound alkalinization
JP4634027B2 (ja) * 2003-05-16 2011-02-16 花王株式会社 ビタミンｄ様活性代替用剤
US7276486B2 (en) * 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
BRPI0508761A (pt) * 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
US20090004182A1 (en) * 2004-10-13 2009-01-01 The Ohio State University Research Foundation Methods to Treat or Prevent Viral-Associated Lymphoproliferative Disorders
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
US20070048391A1 (en) * 2005-08-23 2007-03-01 Cambridgemed, Inc. Composition for reduction of scar formation on wound scar
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
ES2647472T3 (es) 2006-10-03 2017-12-21 Genzyme Corporation Anticuerpos contra TGF-BETA para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
US8070895B2 (en) 2007-02-12 2011-12-06 United States Gypsum Company Water resistant cementitious article and method for preparing same
US8329308B2 (en) 2009-03-31 2012-12-11 United States Gypsum Company Cementitious article and method for preparing the same
GB0910078D0 (en) * 2009-06-11 2009-07-22 Renovo Ltd Uses of mannose-6-phosphate
GB0916333D0 (en) 2009-09-17 2009-10-28 Renovo Ltd Improvement of tendon repair
GB0916334D0 (en) * 2009-09-17 2009-10-28 Renovo Ltd Inhibition of tendon adhesions
PT2835053T (pt) 2010-03-12 2016-07-14 Genzyme Corp Terapêutica combinada para o tratamento do cancro da mama
US20140170236A1 (en) * 2010-11-05 2014-06-19 Priscilla Hayes Petty Use of phosphoric acid
KR20130131414A (ko) 2010-12-27 2013-12-03 엘에스아이피 환도 운에이고우도우가이샤 ｉＰＳ 세포와 그 제조법
EP2737083A1 (de) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Verfahren zur diagnose und behandlung des myhre-syndroms
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
ES2897740T3 (es) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
PL3064222T3 (pl) 2013-10-31 2021-04-19 Kyoto Prefectural Public University Corporation Lek terapeutyczny zawierający inhibitor sygnału tgf-beta w chorobach związanych z retikulum endoplazmatycznym i śmiercią komórki w śródbłonku rogówki
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2023172636A1 (en) * 2022-03-08 2023-09-14 University Of Mississippi Medical Center Articles and methods for improved tissue healing
CN115260256A (zh) * 2022-07-22 2022-11-01 河南中医药大学 一种甘露糖磷酸化衍生物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756953A (fr) * 1969-10-02 1971-04-01 Merck & Co Inc Potentialisation d'antibiotiques
JPS5631156B2 (de) * 1973-09-25 1981-07-20
IT1170618B (it) * 1981-01-13 1987-06-03 Foscama Biomed Chim Farma Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati
US4703040A (en) * 1985-04-03 1987-10-27 Markov Angel K Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP)
DE3686022D1 (de) * 1985-10-22 1992-08-20 Silvetti Sen Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
US4889844A (en) * 1985-10-22 1989-12-26 Silvetti Sr Anthony N Fructose containing wound healing preparation
AU607690B2 (en) * 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
JPS62243675A (ja) * 1986-04-15 1987-10-24 Kao Corp ｐＨ緩衝法
EP0429522B1 (de) * 1988-08-19 1996-06-26 The Australian National University Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel
GB8917414D0 (en) * 1989-07-29 1989-09-13 Translift Material Handling Narrow aisle lift truck
AU654938B2 (en) * 1989-09-29 1994-12-01 La Jolla Cancer Research Foundation Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
SE8904354D0 (sv) * 1989-12-21 1989-12-21 Matti Siren A pharmaceutical composition
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
JPH0558868A (ja) * 1991-08-27 1993-03-09 Kao Corp 親水性紫外線吸収剤及びこれを含有する化粧料
AU3943793A (en) * 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
JPH09155319A (ja) * 1995-12-13 1997-06-17 Takeo Tsutsui 重金属含有焼却灰等、シュレッダーダストの無公害化処理方法および再利用材の製造方法

Also Published As

Publication number Publication date
WO1993018777A1 (en) 1993-09-30
ATE196847T1 (de) 2000-10-15
GB9305344D0 (en) 1993-05-05
GR3035117T3 (en) 2001-03-30
GB2265310B (en) 1996-09-25
NZ249915A (en) 1996-08-27
NO943451L (no) 1994-09-16
ZA931869B (en) 1994-09-16
ES2151903T3 (es) 2001-01-16
SG49899A1 (en) 1998-06-15
EP0728006A1 (de) 1996-08-28
JP3930556B2 (ja) 2007-06-13
DK0728006T3 (da) 2000-10-30
DE69329559T2 (de) 2001-05-31
NO943451D0 (no) 1994-09-16
GB2265310A (en) 1993-09-29
JPH07504909A (ja) 1995-06-01
GB9205800D0 (en) 1992-04-29
PT728006E (pt) 2001-04-30
CA2130805C (en) 2003-06-24
EP0728006B1 (de) 2000-10-11
CA2130805A1 (en) 1993-09-30
AU667887B2 (en) 1996-04-18
IL105079A (en) 1998-06-15
US5520926A (en) 1996-05-28
IL105079A0 (en) 1993-07-08
NO306808B1 (no) 1999-12-27
AU3759093A (en) 1993-10-21

Similar Documents

Publication Publication Date Title
DE69329559D1 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE309795T1 (de) Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
AU5144396A (en) Trisubstituted phenyl derivatives
ATE407677T1 (de) Gereinigte zubereitungen von 10-propargyl-10- deazaaminopterin und verfahren zu ihrer verwendung in der tumorbehandlung
ATE159937T1 (de) 1,4-disubstituierte piperazine zur behandlung von asthma und entzündungen der atemwege
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE275964T1 (de) Verwendung von betalycan zur verminderung der narbenbildung
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE69124382D1 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE200865T1 (de) Verwendung von phosphorderivaten von alkaloiden zur behandlung von endokrinopathien
DE59409813D1 (de) Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition